Medications
Anti-cancer drug safe and effective for treating light chain (AL) amyloidosis
There's a new treatment option available for patients with AL amyloidosis: daratumumab.
Jan 27, 2020
0
10
Al Amyloidosis
Oncology & Cancer
High dose chemo and stem cell transplantation results in long-term survival for amyloid patients
Patients with Light-chain (AL) amyloidosis who are treated with high-dose chemotherapy (melphalan) and autologous (one's own) stem cell transplantation (HDM/SCT) have the greatest success for long-term survival.
Oct 8, 2015
0
5
Oncology & Cancer
Powerful myeloma treatment regimen shows promise for AL amyloidosis
Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating ...
Feb 13, 2012
0
0
Oncology & Cancer
With promising results from emerging therapies, research yields hope for amyloidosis
Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies involving researchers in the Abramson Cancer Center and the Perelman School of Medicine at the ...
Dec 1, 2016
0
0
Cardiology
Three-drug tx ups survival in light-chain amyloidosis
(HealthDay)—For patients with heart failure due to light-chain amyloidosis (AL), three-drug therapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved survival, according to a ...
Jun 21, 2016
0
34
Cardiology
New heart imaging test identifies improved outcomes in patients with amyloidosis
Researchers at Boston Medical Center (BMC) have reported that a new heart imaging test can determine whether cardiac amyloidosis patients are expected to survive after a stem cell transplant. They accomplished this by analyzing ...
Dec 12, 2016
0
0
Diseases, Conditions, Syndromes
Serum free light chain level increase precedes amyloidosis
(HealthDay)—Increased serum free light chains (FLCs) precede the presentation of immunoglobulin light chain amyloidosis (AL amyloidosis), according to a study published online July 14 in the Journal of Clinical Oncology.
Jul 25, 2014
0
0
Medical research
Stem cell transplantation for AL amyloidosis leads to long-term survival and possible cure in selected patients
AL amyloidosis is a life-threatening disease related to bone marrow cancer and multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e. plasma cells) do not function properly and generate ...
Jul 14, 2022
0
3
Oncology & Cancer
Racial/ethnic minorities comprise small portion of patients referred with AL amyloidosis
Despite being theoretically at an increased risk for AL amyloidosis, underrepresented minorities make up only a small percentage of patients seen at specialized treatment centers for this disease.
Nov 10, 2020
0
0
Medical research
Review highlights advances and future needs in AL amyloidosis treatment
AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death.
Jun 26, 2024
0
0
Amyloid Light-chain (AL) amyloidosis, primary systemic amyloidosis (PSA) or just primary amyloidosis is the most common form of systemic amyloidosis in the US. The disease is caused when a person's antibody-producing cells do not function properly and produce abnormal protein fibers made of components of antibodies called light chains. These light chains come together to form amyloid deposits in different organs which can cause serious damage to these organs. Abnormal light chains in blood and urine are sometimes referred to as "M-protein" or "Bence Jones protein".
This text uses material from Wikipedia licensed under CC BY-SA
